Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)

Completed · Phase 1 · Has a placebo group

Conditions studied: Chronic Obstructive Pulmonary Disease

In brief

The primary objective of the study is to assess the safety and tolerability of multiple infusions of andecaliximab (formerly GS-5745) in participants with chronic obstructive pulmonary disease (COPD) as assessed by adverse events (AEs) and laboratory abnormalities.

Key facts

Study ID

NCT02077465

Run by

Gilead Sciences

People needed

11

Starts

2014-03-11

Expected to finish

2014-10-27

Last updated by the study team

2020-09-09

Who can join

Age: 40 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Advanced Pharma CR, LLC — Miami, Florida, United States
• Elite Research Institute — Miami, Florida, United States
• Compass Research, LLC — Orlando, Florida, United States
• University at Buffalo CTRC — Buffalo, New York, United States
• Volunteer Research Group — Knoxville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.